CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Otonomy Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Otonomy Inc
5626 OBERLIN DRIVE, SUITE 100
Phone: (858) 768-7823p:858 768-7823 SAN DIEGO, CA  92121  United States Fax: (302) 636-5454f:302 636-5454

This company ceased filing statements with the SEC on 4/4/2023.
On 3/27/2023, Otonomy, Inc. filed a certificate of dissolution with the State of Delaware. In accordance with the Plan of Dissolution, the company instructed its transfer agent to close the company’s stock transfer books and discontinue recording transfers of the company’s common stock effective as of 4:00 p.m., Eastern time, on 3/27/2023.
On 3/28/2023, Otonomy, Inc. closed the sale of its assets to Prevail Therapeutics, Inc.
This company is no longer actively traded on any major stock exchange.

Business Summary
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Secretary DavidMaggio 3/31/2023 3/31/2023
Director H. MichaelHogan 2/15/2023 2/15/2023

Business Names
Business Name
7OT
OTIC
Otonomy, Inc.

General Information
Number of Employees: 51 (As of 12/31/2021)
Outstanding Shares: 68,527,264 (As of 2/3/2023)
Shareholders: 17
Stock Exchange: OTC
Federal Tax Id: 262590070
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 12, 2024